Cellular Biomedicine Group (CBMG) Given Coverage Optimism Rating of 0.16

News headlines about Cellular Biomedicine Group (NASDAQ:CBMG) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 48.4686522794268 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Separately, Maxim Group set a $18.00 target price on shares of Cellular Biomedicine Group and gave the company a “buy” rating in a report on Wednesday, August 9th.

ILLEGAL ACTIVITY WARNING: “Cellular Biomedicine Group (CBMG) Given Coverage Optimism Rating of 0.16” was reported by Stock Observer and is the property of of Stock Observer. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/10/13/cellular-biomedicine-group-cbmg-given-coverage-optimism-rating-of-0-16.html.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.

Insider Buying and Selling by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply